264 related articles for article (PubMed ID: 30868270)
1. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
2. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
3. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
[TBL] [Abstract][Full Text] [Related]
4. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
[TBL] [Abstract][Full Text] [Related]
5. The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.
Ouchi Y; Nakatsukasa K; Sakaguchi K; Morita M; Koyama H; Matsuda T; Kato M; Konishi E; Ono H; Taguchi T
J Bone Miner Metab; 2021 Mar; 39(2):224-229. PubMed ID: 32889575
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
7. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Fan M; Kim D
Breast Cancer Res Treat; 2009 Nov; 118(1):81-7. PubMed ID: 19308727
[TBL] [Abstract][Full Text] [Related]
8. Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
Ther Clin Risk Manag; 2018; 14():1213-1218. PubMed ID: 30022834
[TBL] [Abstract][Full Text] [Related]
9. Denosumab effect on bone mineral density and urinary-NTX in breast cancer patients receiving aromatase inhibitors.
Shibata M; Okumura M; Kawano S; Noda H; Toyota C; Mizuno Y
J Bone Miner Metab; 2023 Jul; 41(4):567-574. PubMed ID: 37247110
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer.
Kong SH; Kim JH; Kim SW; Shin CS
J Bone Miner Metab; 2020 Sep; 38(5):730-736. PubMed ID: 32405760
[TBL] [Abstract][Full Text] [Related]
11. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
Su G; Xiang Y; He G; Jiang C; Li C; Yan Z; Zhong Y
Arch Med Res; 2014 Oct; 45(7):570-9. PubMed ID: 25450582
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
14. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
15. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
16. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors.
Galvano A; Gristina V; Scaturro D; Bazan Russo TD; Tomasello S; Vitagliani F; Carità F; La Mantia M; Fulfaro F; Bazan V; Mauro GL; Russo A
Front Endocrinol (Lausanne); 2023; 14():1297950. PubMed ID: 38075057
[TBL] [Abstract][Full Text] [Related]
17. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
Catalano A; Gaudio A; Morabito N; Basile G; Agostino RM; Xourafa A; Atteritano M; Morini E; Natale G; Lasco A
J Endocrinol Invest; 2017 Aug; 40(8):851-857. PubMed ID: 28332172
[TBL] [Abstract][Full Text] [Related]
18. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
Khan AA; AbuAlrob H; M'Hiri I; Ali DS; Dandurand K; Said H; Alkassem H; Hakami Y; Hweija I; Iqbal S; Romanovschi M; Mehmood S; Zariffeh H; Guyatt G; Ibrahim Q; Brignardello-Petersen R; Syed HI
Endocrine; 2023 Jun; 80(3):647-657. PubMed ID: 37186270
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Gnant M; Pfeiler G; Steger GG; Egle D; Greil R; Fitzal F; Wette V; Balic M; Haslbauer F; Melbinger-Zeinitzer E; Bjelic-Radisic V; Jakesz R; Marth C; Sevelda P; Mlineritsch B; Exner R; Fesl C; Frantal S; Singer CF;
Lancet Oncol; 2019 Mar; 20(3):339-351. PubMed ID: 30795951
[TBL] [Abstract][Full Text] [Related]
20. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
Miyauchi A; Hamaya E; Yang W; Nishi K; Libanati C; Tolman C; Shimauchi J
J Bone Miner Metab; 2021 Mar; 39(2):278-288. PubMed ID: 33057807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]